Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Emmaus Life Sciences Inc (EMMA)

Emmaus Life Sciences Inc (EMMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 19,328
  • Shares Outstanding, K 49,558
  • Annual Sales, $ 20,610 K
  • Annual Income, $ -15,950 K
  • 60-Month Beta 2.40
  • Price/Sales 0.91
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EMMA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings -0.01 on 11/14/22
  • Next Earnings Date 11/11/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2800 +25.00%
on 11/16/22
0.5000 -30.00%
on 12/01/22
-0.0940 (-21.17%)
since 11/04/22
3-Month
0.0706 +395.75%
on 10/12/22
0.5000 -30.00%
on 12/01/22
unch (unch)
since 09/01/22
52-Week
0.0706 +395.75%
on 10/12/22
1.7800 -80.34%
on 12/09/21
-1.2000 (-77.42%)
since 12/03/21

Most Recent Stories

More News
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has been issued a Registration...

EMMA : 0.3500 (-10.26%)
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.3500 (-10.26%)
Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...

EMMA : 0.3500 (-10.26%)
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.3500 (-10.26%)
Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.3500 (-10.26%)
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand...

AZ.TO : 6.19 (unch)
AAZZF : 10.8545 (+0.13%)
ACST : 0.3957 (-7.72%)
ATNM : 10.75 (-4.61%)
ADCO.TO : 0.2900 (+1.75%)
ADCOF : 0.1800 (-15.05%)
ALIM : 3.51 (-1.96%)
ACOGF : 0.2807 (+10.08%)
AMST : 0.3119 (-0.86%)
ANVS : 12.35 (-1.20%)
ANPC : 3.89 (+1.04%)
ARC : 3.00 (+0.33%)
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.3500 (-10.26%)
Emmaus Life Sciences Announces Informational Stockholders Meeting

--Meeting Will be Open to the Public--

EMMA : 0.3500 (-10.26%)
UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi...

EMMA : 0.3500 (-10.26%)
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi...

EMMA : 0.3500 (-10.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.3500
2nd Resistance Point 0.3500
1st Resistance Point 0.3500
Last Price 0.3500
1st Support Level 0.3500
2nd Support Level 0.3500
3rd Support Level 0.3500

See More

52-Week High 1.7800
Fibonacci 61.8% 1.1270
Fibonacci 50% 0.9253
Fibonacci 38.2% 0.7236
Last Price 0.3500
52-Week Low 0.0706

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar